Literature DB >> 28832959

Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services.

Rakesh Popat1, Emma Dowling2, Sufyan Achhala1, Devanshi Pandit1, Neil Rabin1, Charalampia Kyriakou1, Stephen Mackinnon1, Kwee Yong1, Ashutosh Wechalekar1.   

Abstract

Entities:  

Keywords:  immunotherapy; monoclonal antibodies; myeloma; myeloma therapy

Mesh:

Substances:

Year:  2017        PMID: 28832959     DOI: 10.1111/bjh.14897

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  1 in total

1.  Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Authors:  Efstathios Kastritis; Ioannis V Kostopoulos; Evangelos Terpos; Bruno Paiva; Despina Fotiou; Maria Gavriatopoulou; Nikolaos Kanellias; Dimitrios C Ziogas; Maria Roussou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Ioannis P Trougakos; Ourania Tsitsilonis; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.